How to Buy Artiva Biotherapeutics Stock
Artiva Biotherapeutics Inc
Artiva Biotherapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
Artiva Biotherapeutics stock last closed at $2.40, up 7.14% from the previous day, and has decreased N/A in one year. It has underperformed other stocks in the Biotechnology industry by N/A percentage points. Artiva Biotherapeutics stock is currently +34.83% from its 52-week low of $1.78, and -86.14% from its 52-week high of $17.31.
As of Apr 21, 2025, there are 24.36M shares of ARTV outstanding. The market capitalization of ARTV is $58.47M. In the past 24 hours, 370,580 ARTV shares were traded.
How to Buy Artiva Biotherapeutics Stock
Wondering how to invest in Artiva Biotherapeutics stock? Here's how.
- Decide where to buy Artiva Biotherapeutics stock: You need to pick an online brokerage, but don't worry - we've tested dozens of online stock brokerages and apps to help you choose where to buy Artiva Biotherapeutics stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Put funds into your brokerage account: Select your payment method and add your details.
- Analyze Artiva Biotherapeutics stock: The Artiva Biotherapeutics ticker symbol is ARTV. Is Artiva Biotherapeutics stock a good investment? Should you buy shares of ARTV? How do ARTV's underlying business fundamentals look? Do top analysts think Artiva Biotherapeutics is a good buy? Why has ARTV's stock price moved recently? (Hint: Our stock market analysis website can help you evaluate if ARTV is a good stock to buy).
- Place your ARTV buy order: Decide if you will purchase ARTV shares at the current market price or use a limit order to purchase ARTV stock at a specific price.
- Get updates on your ARTV investment: Create a watchlist to keep track of your new investment in Artiva Biotherapeutics stock.
Step 1: Decide where to buy Artiva Biotherapeutics stock
You will need a brokerage account to access the NASDAQ market and buy ARTV shares.
Our favorite brokerage: eToro
In our opinion, eToro is the best stock brokerage. eToro gives you:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to world financial markets: From Tech to Energy, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro has a community of more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've picked the best brokerage, it's time to fill out some personal information so you can buy ARTV today.
How to Create a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal info to start your new brokerage account.
- Submit your info by clicking the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you have filled out your info on the stocks app, your next step is to transfer the money for your investment:
Watch the walkthrough below if you need help depositing money into your investment account.
Step 4: Analyze Artiva Biotherapeutics stock
Once you have chosen the best place to buy Artiva Biotherapeutics stock, it's important to evaluate their stock prior to buying, so you can understand the risk and upside.
Artiva Biotherapeutics Metrics
Artiva Biotherapeutics Due Diligence Checks
WallStreetZen was designed to help part-time investors do more in-depth fundamental analysis quickly.
You can see all of the due diligence checks on ARTV's stock page.
Is ARTV stock properly valued?
You can use many financial metrics, analyses, models, and charts to gauge ARTV's fair value.
Using relative valuations ratios:
- ARTV may be undervalued based on its P/B ratio of 0.31x, relative to Biotechnology industry P/B ratio of 4.04x
You can do additional valuation research on ARTV's stock here.
A quick look at ARTV Financials
Positive Health Checks:
- ARTV has cash burn of 55674000. It has sufficient cash and short-term investments to cover this for at least one year.
- ARTV has $185.69M in cash and short term investments. This is sufficient to cover its annual cash burn of $55.67M.
- There are more short-term assets than short-term liabilities on the ARTV balance sheet.
- ARTV has a low debt to equity ratio of 0.12.
- There are more short-term assets than long-term liabilities on the ARTV balance sheet.
Negative Health Checks:
- ARTV profit margin has gone down from -85.8% to -26,045% in the past year.
Is ARTV stock a Buy, Hold, or Sell, according to analysts?
Out of 4 Equities analysts who research ARTV, the consensus analyst rating on Artiva Biotherapeutics is a Strong Buy
Please note that analyst forecasts are not recommendations, nor are they financial advice.
You can dive deeper into what analysts are projecting on the Artiva Biotherapeutics stock forecast page.
ARTV Technicals
How are ARTV Revenues/Earnings doing?
Last year, ARTV revenue was $251.00k. During the past 2 year, ARTV's revenue has grown by -77.44% per year. This was slower than the Biotechnology industry average of 44.31%.
Learn more about ARTV's earnings and revenue performance here.
Latest Insiders Trades at ARTV
In the past year, executives and large shareholders at ARTV have bought more shares than they have sold.
5am Partners VI LLC, 10% Owner of ARTV, was the latest ARTV insider to buy. They bought $9,999,996.00 worth of ARTV stock on Jul 22, 2024.
Dig into more about who owns ARTV stock here.
Can I rely on ARTV as an income stream?
No, Artiva Biotherapeutics doesn't provide an income stream by paying out dividends.
ARTV Social Trading Data
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Place your ARTV buy order
There are two main types of orders:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are usually fine. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a particular price, use a limit order.
Press the Open Trade button and eToro will execute your order.
If you require additional help investing in stocks on eToro, watch the how to video below:
Step 6: Get updates on your ARTV investment
Now that you own some ARTV stock, you'll want to stay up-to-date on your company.
Start a watchlist to track the latest developments regarding your ARTV stock.
ARTV Feed
How to Buy Stock in Artiva Biotherapeutics
To reiterate, here are the 6 steps to buy Artiva Biotherapeutics stock:
- Decide where to buy Artiva Biotherapeutics stock
- Sign up for your brokerage account
- Put funds into your brokerage account
- Analyze Artiva Biotherapeutics stock
- Place your ARTV buy order
- Get updates on your ARTV investment
If you are looking for a brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to track your new investment in Artiva Biotherapeutics, add ARTV to your watchlist below.
More Content You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.